2-(4-(piperidin-1-yl)phenyl)-2H-benzo[d][1,2,3]triazol-5-amine | 945527-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-(4-(piperidin-1-yl)phenyl)-2H-benzo[d][1,2,3]triazol-5-amine
• 英文别名: 2-(4-Piperidin-1-ylphenyl)benzotriazol-5-amine
• CAS: 945527-98-0
• 化学式: C₁₇H₁₉N₅
• 分子量: 293.371
• InChiKey: PAFPUTVDJTZYRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  60
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
  申请人：Wynne Graham Michael

  公开号：US20100048660A1

  公开（公告）日：2010-02-25

  There are disclosed compound of Formula (I) or (II) wherein A 1 , A 2 , A 3 , A 4 and A 5 , which may be the same or different, represent N or CR 1 , R 9 represents -L-R 3 , in which L is a single bond or a linker group and R 3 represents hydrogen or a substituent and in addition, when an adjacent pair of A 1 -A 4 each represent CR 1 , then the adjacent carbon atoms, together with their substituents may form a ring B, when A 5 represents CR 1 , then A 5 and N—R 9 , together with their substituents may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.

  公开了化合物的式子（I）或（II），其中A1、A2、A3、A4和A5，可以相同也可以不同，代表N或CR1，R9代表-L-R3，其中L是单键或连接基团，R3代表氢或取代基团，此外，当相邻的A1-A4成对代表CR1时，它们相邻的碳原子及其取代基团可以形成环B，当A5代表CR1时，A5和N—R9及其取代基团可以形成环C，或其药学上可接受的盐，在制造用于治疗和/或预防杜兴肌肉萎缩症、贝克肌肉萎缩症或消瘦症的药物中使用。
• Drug Combinations for the Treatment of Duchenne Muscular Dystrophy
  申请人：Wynne Graham Michael

  公开号：US20100168072A1

  公开（公告）日：2010-07-01

  Combinations comprising (or consisting essentially of) one or more compounds of the formula (I) or (II) with one or more ancillary compounds, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.

  本发明涉及由公式（I）或（II）中的一个或多个化合物与一个或多个辅助化合物组成的组合物，以及制备这些组合物的方法，以及这些组合物的各种治疗用途。还提供了含有这些组合物的药物组合物，以及使用这些组合物治疗杜氏肌营养不良症、贝克肌营养不良症或消瘦的方法。
• DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
  申请人：Summit Corporation Plc

  公开号：EP2170325A2

  公开（公告）日：2010-04-07
• [EN] TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY<br/>[FR] TRAITEMENT DE LA DYSTROPHIE MUSCULAIRE DE DUCHENNE
  申请人：VASTOX PLC

  公开号：WO2007091107A1

  公开（公告）日：2007-08-16

  [EN] There are disclosed compound of Formula (I) or (II) wherein A¹, A², A³, A⁴and A⁵, which may be the same or different, represent N or CR¹, R₉ represents - L -R³, in which L is a single bond or a linker group and R³ represents hydrogen or a substituent and in addition, when an adjacent pair of A¹ - A⁴ each represent CR¹, then the adjacent carbon atoms, together with their substituents may form a ring B, when A⁵ represents CR¹, then A⁵ and N - R⁹, together with their substituents may form a ring C, or a harmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.
  [FR] La présente invention porte sur le composé représenté par la formule (I) ou (II) dans laquelle: A¹, A², A³, A⁴ et A⁵, qui peuvent être identiques ou différents, désignent N ou CR¹; R₉ désigne - L -R³, L désignant une liaison simple ou un groupe de liaison et R³ désignant hydrogène ou un substituant; lorsqu'une paire adjacente de A¹ - A⁴ désigne chacune CR¹, les atomes de carbone adjacents, de même que leurs substituants, peuvent former un cycle B; lorsque A⁵désigne CR¹, A⁵ et N - R⁹, de même que leurs substituants, peuvent former un cycle C; ou un sel pharmaceutiquement acceptable de ce composé, utilisé dans la fabrication d'un médicament servant au traitement thérapeutique et/ou prophylactique de la dystrophie musculaire de Duchenne, de la dystrophie musculaire de Becker, ou de la cachexie.
• [EN] DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY<br/>[FR] COMBINAISONS DE MÉDICAMENTS POUR LE TRAITEMENT DE LA DYSTROPHIE MUSCULAIRE DE DUCHENNE
  申请人：SUMMIT CORP PLC

  公开号：WO2009019505A2

  公开（公告）日：2009-02-12

  Combinations comprising (or consisting essentially of) one or more compounds of the formula (I) or (II) with one or more ancillary compounds, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.